Magnetic resonance imaging assessment of chemotherapy-related adipocytic maturation in myxoid/round cell liposarcomas: specificity and prognostic value.
Adipocytes
/ drug effects
Adult
Aged
Anthracyclines
/ therapeutic use
Antineoplastic Agents
/ therapeutic use
Cell Differentiation
/ drug effects
Chemotherapy, Adjuvant
Contrast Media
Disease-Free Survival
Female
Humans
Kaplan-Meier Estimate
Liposarcoma, Myxoid
/ diagnostic imaging
Magnetic Resonance Imaging
Male
Middle Aged
Neoadjuvant Therapy
Proportional Hazards Models
Radiotherapy, Adjuvant
Retrospective Studies
Sensitivity and Specificity
Tumor Burden
Journal
The British journal of radiology
ISSN: 1748-880X
Titre abrégé: Br J Radiol
Pays: England
ID NLM: 0373125
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
pubmed:
28
2
2020
medline:
5
6
2020
entrez:
28
2
2020
Statut:
ppublish
Résumé
To investigate the specificity, clinical implication and prognostic value of MRI adipocytic maturation (MAM) in myxoid/round cells liposarcomas (MRC-LPS) treated with neoadjuvant chemotherapy (NAC). Of the 89 patients diagnosed with MRC-LPS at our sarcoma reference center between 2008 and 2018, 28 were included as they were treated with NAC, surgery and radiotherapy. All patients underwent contrast-enhanced MRIs at baseline and late evaluation. A control cohort of 13 high-grade pleomorphic and dedifferentiated LPS with same inclusion criteria was used to evaluate the specificity of MAM in MRC-LPS. Two radiologists analyzed the occurrence of MAM, changes in the tumor architecture, shape and surrounding tissues during NAC. Pathological features of tumor samples were reviewed and correlated with MRI. Metastatic relapse-free survival was estimated with Kaplan-Meier curves and Cox models. Associations between prognostic T1-based delta-radiomics features and MAM were investigated with Student MAM was more frequent in MRC-LPS ( MAM seems a neutral event during NAC. MAM predominated in MRC-LPS and was not specific of a type of chemotherapy. Occurrence of MAM was not associated with better patients' metastasis free survival.
Identifiants
pubmed: 32105502
doi: 10.1259/bjr.20190794
doi:
Substances chimiques
Anthracyclines
0
Antineoplastic Agents
0
Contrast Media
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM